Home > Insider Trading > Filing (0000899243-20-028809)

Filing Details

Accession Number:: 0000899243-20-028809
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-20 20:07:28
Reporting Period:: 2020-10-16

Accepted Time:: 2020-10-20 20:07:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659352	Codiak Biosciences Inc.	CDAK	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219039	Keith Crandell	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219042	Robert Nelsen	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1219043	Clinton Bybee	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1605598	Arch Venture Fund Viii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1616165	Arch Venture Partners Viii, Llc	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1616176	Arch Venture Partners Viii, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No
1617237	Arch Venture Fund Viii Overage, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-16	1,784,572	$0.00	1,848,535	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	831,521	$0.00	831,521	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	420,368	$0.00	2,268,903	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	326,953	$0.00	1,158,474	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	191,721	$0.00	1,350,195	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-10-16	235,000	$15.00	2,503,903	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-10-16	13,950,000	$0.00	1,784,572	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-10-16	6,500,000	$0.00	831,521	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-10-16	3,000,000	$0.00	420,368	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-10-16	2,333,333	$0.00	326,953	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-10-16	1,320,097	$0.00	191,721	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.8170 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date.
Shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Each share of Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.1366 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.